Clinical Trial

LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 3, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The LaCE study is a double-blind, randomised, placebo-controlled trial examining the effectiveness of the probiotic Lactobacillus paracasei LPB27 in treating eczema in young children.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-02; most recent amendment 2025-05-28.
Status change: Not Yet Recruiting → Recruiting 2025-05-28
Trial Details
NCT Number NCT06584552
Lead Sponsor The University of New South Wales
Collaborators: Evolution Health Pty Ltd
Conditions Eczema, Allergy
Enrollment 100 participants
Start Date 2024-11-15
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-06-03